Acta dermato-venereologica最新文献_第3页

Unilateral Maculopapular Rash in a Child: A Quiz.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.43059

Katarzyna Jankowska, Jozef Kokoszka, Jacek C Szepietowski

引用次数: 0

Patient Needs and Treatment Goals in Chronic Atopic Pruritus: Does Eczema Make a Difference?

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.42773

Svenja Müller, Claudia Zeidler, Christian Mess, Stefan M Kahnert, Bernd Löwe, Angelika Weigel, Felix Witte, Volker Huck, Lynhda Nguyen, Matthias Augustin, Gina Frank, Konstantin Agelopoulos, Henning Wiegmann, Ansgar Köchel, Rupert Conrad, Gudrun Schneider, Stefan W Schneider, Sonja Ständer, Inga Hansen-Abeck, Finn Abeck

{"title":"Patient Needs and Treatment Goals in Chronic Atopic Pruritus: Does Eczema Make a Difference?","authors":"Svenja Müller, Claudia Zeidler, Christian Mess, Stefan M Kahnert, Bernd Löwe, Angelika Weigel, Felix Witte, Volker Huck, Lynhda Nguyen, Matthias Augustin, Gina Frank, Konstantin Agelopoulos, Henning Wiegmann, Ansgar Köchel, Rupert Conrad, Gudrun Schneider, Stefan W Schneider, Sonja Ständer, Inga Hansen-Abeck, Finn Abeck","doi":"10.2340/actadv.v105.42773","DOIUrl":"10.2340/actadv.v105.42773","url":null,"abstract":"Chronic pruritus (≥ 6 weeks) is a frequent symptom in atopic diseases, with phenotypes ranging from non-lesional skin to inflammatory diseases like atopic dermatitis. Data on patients' needs and treatment goals depending on the skin phenotype and disease burden are limited. This study aimed to analyse the impact of distinct phenotypes of chronic atopic pruritus on disease burden and treatment goals. Another objective was to investigate whether the disease burden influences the treatment goals. Patient-reported outcomes of 1,086 adult patients (n = 529 with atopic dermatitis, n = 557 with chronic pruritus on non-lesional skin with atopic skin diathesis) were analysed age- and gender-matched (mean age 49.7 ± 19.0 years; n = 605 female [55.7%]), comparing pruritus intensity (Numeric Rating Scale), quality of life (Dermatology Life Quality Index, ItchyQol), anxiety and depression (Hospital Anxiety and Depression Scale), and patient needs (Patient Needs Questionnaire of the Patient Benefit Index-Pruritus). Although the disease burden was significantly higher in patients with atopic dermatitis (prolonged disease duration, increased quality of life impairment, higher pruritus intensity), the treat-ment goals of both phenotypes matched in 92.6%. The most important needs were to no longer experience itching, find a clear diagnosis and therapy, and have confidence in the therapy.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42773"},"PeriodicalIF":3.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143612935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pemphigoid with Autoantibodies against p200 and all Subunits of Laminin 332 Associated with Drug Eruption Caused by Piperacillin/tazobactam.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.41369

Hanako Miyahara, Rie Honda, Shusaku Ito, Norito Ishii, Toshifumi Nomura

引用次数: 0

Bullous Haemorrhagic Vasculitis Associated with Adalimumab in a Child with Juvenile Idiopathic Arthritis.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.42482

Valeria Biasotti, Dalila Iacono, Chiara Pilotto, Barbara Bigucci, Giorgia Martini

引用次数: 0

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.42275

Laura Calabrese, Elisa Cinotti, Martina D'Onghia, Alessandra Cartocci, Pietro Rubegni, François Maccari, Claire Boulard, Ziad Reguiai, Pierre-André Becherel, Caroline Jacobzone, Edouard Begon, Charlotte Fite, Beatrice Walls, Anne Laure Liegeon, Josiane Parier, Guillaume Chaby, Jean-Luc Perrot

{"title":"Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study.","authors":"Laura Calabrese, Elisa Cinotti, Martina D'Onghia, Alessandra Cartocci, Pietro Rubegni, François Maccari, Claire Boulard, Ziad Reguiai, Pierre-André Becherel, Caroline Jacobzone, Edouard Begon, Charlotte Fite, Beatrice Walls, Anne Laure Liegeon, Josiane Parier, Guillaume Chaby, Jean-Luc Perrot","doi":"10.2340/actadv.v105.42275","DOIUrl":"https://doi.org/10.2340/actadv.v105.42275","url":null,"abstract":"Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce. This prospective, observational, multicentric study aimed to assess the long-term effectiveness and safety of tralokinumab in patients with AD in a real-world setting. Primary outcomes included 50%, 75%, and 90% improvement in Eczema Area and Severity Index score (EASI50, EASI75, EASI90, respectively) and improvements in Dermatology Life Quality Index (DLQI) at 1 year. A total of 136 patients with AD were enrolled in the study; data at 1-year follow-up were available for 111 patients. After 1 year, 68.5% and 33.3% of patients achieved an EASI75 and EASI90, respectively. A significantly higher percentage of patients with than without foot involvement achieved EASI50 (p = 0.009) and EASI75 (p = 0.022). Similarly, hand involvement was significantly associated with higher EASI50 response (p = 0.005). Median DLQI score decreased from 9.00 (interquartile range (IQR): 6.00, 13.75) to 1.00 (IQR: 0.00, 4.00) after 1 year of treatment. Adverse events included blepharitis (n = 10), conjunctivitis (n = 6), and injection-site reactions (n = 2). Tralokinumab can be an effective and safe treatment for patients with moderate-to-severe AD. Involvement of certain body areas, such as hands and feet, might positively predict a clinical response to tralokinumab.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42275"},"PeriodicalIF":3.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143612932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Features, Diagnosis and Treatment of Different Types of Paediatric Pemphigus.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-09 DOI: 10.2340/actadv.v105.42776

An-Wei Chen, Li Liu, Huan Yang, Xiao-Yan Luo, Juan Xiang

{"title":"Clinical Features, Diagnosis and Treatment of Different Types of Paediatric Pemphigus.","authors":"An-Wei Chen, Li Liu, Huan Yang, Xiao-Yan Luo, Juan Xiang","doi":"10.2340/actadv.v105.42776","DOIUrl":"10.2340/actadv.v105.42776","url":null,"abstract":"Pemphigus is a rare and life-threatening autoimmune disease that is easily ignored in children. This study aimed to attract attention to pemphigus in the paediatric population for better understanding and recognition of the clinical characteristics and management in children's different subtypes of pemphigus. The case series involved a retrospective record review of 3 patients who were referred to a department of dermatology from January 2022 to January 2024. All patients experienced a delayed diagnosis, but were eventually definitively diagnosed with pemphigus vulgaris, pemphigus foliaceus, and pemphigus erythematosus, because they all have intraepidermal blisters and elevated serum antibodies against Dsg1/Dsg3. In all 3 cases, systemic corticosteroids were used in combination with or without steroid-sparing adjuvants. The patient with pemphigus vulgaris experienced a recurrence due to discontinuous treatment; the other 2 patients achieved mostly remission after treatment, with the length of follow-up ranging from 5 to 12 months. Pemphigus in children has its own clinical characteristics and similar literature concerning improved strategies for clinical assessment and treatments are reviewed and discussed.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42776"},"PeriodicalIF":3.5,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple Biologics Treatment Failures in Patients with Psoriasis: A Case Series of 4 Patients.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-09 DOI: 10.2340/actadv.v105.42987

Mikkel Bak Jensen, Nikolai Loft, Claus Zachariae, Lone Skov

引用次数: 0

Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-09 DOI: 10.2340/actadv.v105.41504

Anne R Schlosser, Lars Nijman, Renske Schappin, Tamar E C Nijsten, Dirkjan Hijnen

{"title":"Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice.","authors":"Anne R Schlosser, Lars Nijman, Renske Schappin, Tamar E C Nijsten, Dirkjan Hijnen","doi":"10.2340/actadv.v105.41504","DOIUrl":"10.2340/actadv.v105.41504","url":null,"abstract":"In recent years, several new systemic agents (biologics and Janus kinase inhibitors [JAKi]) have been registered for the treatment of moderate-to-severe atopic dermatitis (AD). However, comparisons of real-world drug survival data and insights into treatment patterns of these advanced systemics are limited. Data from a prospective observational single-centre registry were collected from 549 adult AD patients (759 treatment courses) receiving biologics (dupilumab, tralokinumab) or JAKi (abrocitinib, baricitinib, upadacitinib) and analysed using Kaplan-Meier survival curves. Cox regression analyses were used to evaluate predictors of survival. Frequencies and percentages summarized data on the initial and subsequent treatments received, with a Sankey diagram illustrating the switching patterns. The 18-month overall drug survival rates for dupilumab, abrocitinib, upadacitinib, tralokinumab, and baricitinib were 70.0%, 51.5%, 48.4%, 39.4%, and 20.4%, respectively. No significant predictors for drug survival were identified. Dupilumab was the predominant initial treatment (87.2%) and upadacitinib the most frequently used second and third treatment. In the total cohort, 57.9% of patients remained on their initial treatment and 26.8% switched to other treatments. In conclusion, dupilumab showed superior survival rates while baricitinib had the lowest survival rate. Frequent switching highlights the need for biomarkers that predict response to advanced systemic treatments to improve attrition rates.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv41504"},"PeriodicalIF":3.5,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Counselling Needs in Atopic Dermatitis: Perspectives on Pregnancy and Treatment. 特应性皮炎的咨询需求：关于怀孕和治疗的观点。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-07 DOI: 10.2340/actadv.v105.42544

Catalina H Skovsgård, Anne Sofie Frølunde, Mette Deleuran, Jacob P Thyssen, Simon F Thomsen, Christian Vestergaard

{"title":"Counselling Needs in Atopic Dermatitis: Perspectives on Pregnancy and Treatment.","authors":"Catalina H Skovsgård, Anne Sofie Frølunde, Mette Deleuran, Jacob P Thyssen, Simon F Thomsen, Christian Vestergaard","doi":"10.2340/actadv.v105.42544","DOIUrl":"10.2340/actadv.v105.42544","url":null,"abstract":"Atopic dermatitis (AD) is a common inflammatory skin disease affecting 5-8% of adults, with many being of reproductive age and potentially experiencing AD- and treatment-related challenges during family planning and pregnancy (FPP). This study examined whether patients with AD receive FPP-related information from their dermatologist and their concerns about pregnancy and breastfeeding. A cross-sectional questionnaire study was conducted among 18-45-year-old patients with AD treated at dermatology departments in university hospitals or private dermatology clinics in Denmark, all undergoing either topical or systemic treatment. A total of 121 patients participated in the study. The most pronounced concern was the heritable nature of AD (88.4%), followed by concerns about the teratogenicity of their treatments (29.8%). Additionally, 37.1% of women expressed concern about their ability to breastfeed. One-third of patients with AD had discussed FPP with their dermatologists prior to pregnancy, and 15% reported having fewer biological children than they desired due to their disease. Adult patients with AD have significant unmet informational needs regarding FPP. Addressing these concerns at appropriate stages in their lives, potentially through structured communication, could provide patients with better opportunities to address their concerns and plan their family life based on comprehensive and accurate information.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42544"},"PeriodicalIF":3.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frequency of TNFalpha, IL17RA, and Act1 Genetic Polymorphisms in a Population with Psoriasis Compared with Healthy Individuals: Results in a Multiracial Population in Rio de Janeiro, Brazil.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-07 DOI: 10.2340/actadv.v105.42017

Ana Luisa Sampaio, Bruna Romana-Souza, Haizza Cristina Cabral de Almeida Monteiro, Camila Oliveira da Silva, Luna Azulay-Abulafia

引用次数: 0